Intraoperative use of remifentanil and opioid induced hyperalgesia/acute opioid tolerance: systematic review

Sang Hun Kim1 *, Nicoleta Stoicea2, Suren Soghomonyan2 and Sergio D. Bergese2,3

1 Department of Anesthesiology and Pain Medicine, School of Medicine, Chosun University, Gwangju, South Korea
2 Department of Anesthesiology, Ohio State University Wexner Medical Center, Columbus, OH, USA
3 Department of Neurological Surgery, Ohio State University Wexner Medical Center, Columbus, OH, USA

**Correspondence:**
Sang Hun Kim, Department of Anesthesiology and Pain Medicine, School of Medicine, Chosun University, Gwangju, South Korea
e-mail: ksh3223@chosun.ac.kr

**INTRODUCTION**

Even though remifentanil increases analgesia and respiratory depression in a dose-dependent manner (Hughes et al., 1992; Egan et al., 1993; Glass et al., 1993; Westmoreland et al., 1993; Kapila et al., 1995), these effects disappear rapidly after discontinuing administration of the drug because of the extremely short elimination half-life (9.5 ± 4 min). Especially, remifentanil has the shortest context-sensitive half-time and terminal elimination half-life among other opioid after 3-h infusion (Kapila et al., 1995). Therefore, remifentanil can be given in high doses throughout surgery without the risk of delayed postoperative recovery or respiratory depression. Because of its pharmacodynamic and pharmacokinetic effects, remifentanil has been used in clinical anesthesia as an induction and maintenance agent, and postoperative pain management in the intensive care units.

Most of the studies conducted with remifentanil showed cardiovascular responses during perioperative manipulations. They recommended a bolus injection of remifentanil of 1 μg/kg as more effective dose in reducing the pressor response during laryngoscopy and tracheal intubation (McAtamney et al., 1998; O’Hare et al., 1999). However, while the cardiovascular responses reaches a peak 1–2 min after laryngoscopy and intubation, and usually subsides within 5–6 min (Singh et al., 1995), the context-sensitive half-time of bolus remifentanil is only 3.2 min (Glass et al., 1993; Kapila et al., 1995). Therefore, remifentanil bolus alone is not enough to attenuate the responses and the use of a bolus-infusion regimen is required (McAtamney et al., 1998). The commonly accepted and recommended dose of remifentanil is 1 μg/kg followed by an infusion of 0.5–1 μg/kg/min for induction of anesthesia or 0.05–2.0 μg/kg/min for maintenance of anesthesia (Burkle et al., 1996; Hall et al., 2000; Sneyd et al., 2001). In postoperative period, remifentanil continuous infusion (CI) also can be used for controlling the pain, and the final remifentanil infusion rates have been reported as 0.05–0.26 μg/kg/min for satisfactory

**Methods:** We reviewed articles analyzing remifentanil AOT and OIH, and focused our literature search on evidence based information. Experimental and clinical studies were identified using electronic searches of Medline (PubMed, Ovid, Springer, and Elsevier, ClinicalKey).

**Results:** Our results showed that the development of remifentanil AOT and OIH is a clinically significant phenomenon requiring further research.

**Discussions and Conclusions:** AOT – defined as an increase in the required opioid dose to maintain adequate analgesia, and OIH – defined as decreased pain threshold after chronic opioid treatment, should be suspected with any unexplained pain report unassociated with the disease progression. The clinical significance of these findings was evaluated taking into account multiple methodological issues including the dose and duration of opioids administration, the different infusion mode, the co-administrated anesthetic drug’s effect, method assessing pain sensitivity, and the repetitive and potentially tissue damaging nature of the stimuli used to determine the threshold during opioid infusion. Future studies need to investigate the contribution of remifentanil induced hyperalgesia to chronic pain and the role of pharmacological modulation to reverse this process.

**Keywords:** remifentanil, opioid-induced hyperalgesia, opioid tolerance, intraoperative, postoperative
analgésia after surgery (Bowdle et al., 1996, 1997; Schuttler et al., 1997; Yarmush et al., 1997; Sneyd et al., 2001).

Common concerns regarding the use of opioids are potential detrimental side effects, physical dependence, and addiction. However, an additional concern has recently risen that these opioids can induce an acute tolerance and hyperalgesia in dose and/or time dependent manner even when used within clinical accepted doses. They provide straight analgesic and antihyperalgesic effects originally, but subsequently are associated with expression of hyperalgesia (Angst and Clark, 2006). The use of opioids may seem to be a double-edged sword. In other words, patients receiving opioids to control their pain somewhat paradoxically may become more sensitive to pain as a direct result of opioid therapy.

Therefore, a review of literature was carried out to analyze acute tolerance and/or hyperalgesia induced by remifentanil in perioperative period using electronic searches of Medline (PubMed, Ovid, Springer, and Elsevier, ClinicalKey). The objective was to address the following issues: (1) what is the definition of acute opioid tolerance (AOT) and opioid-induced hyperalgesia (OIH)? (2) Dose remifentanil may induce the acute tolerance and hyperalgesia? (3) Are AOT and OIH significant enough to consider reducing the dose of remifentanil or adopting preventive modulations?

**DEFINITION OF ACUTE OPIOID TOLERANCE AND OPIOID-INDUCED HYPERALGESIA**

Before we discuss AOT and OIH induced by remifentanil, we have to understand the definitions of AOT and OIH because management for pain control is different according to make a diagnosis one of them; While AOT can be overcome by increasing the dosage, OIH even worsens the pain. Consequently, OIH is reduced by reducing or eliminating the opioid.

Opioid-induced hyperalgesia is defined as a state of nociceptive sensitization, which is characterized by a paradoxical response, whereby a patient receiving opioids for pain treatment might have an increased sensitivity to painful stimuli (Angst and Clark, 2006; Chu et al., 2008). Even though controlled preclinical experiments have defined OIH in animals as a decrease in pain threshold from baseline after chronic administration of opioids (Fishbain et al., 2009), there still is no accepted operational definition of OIH among researchers in human clinical trials; hyperalgesia is defined as decrease in either pain threshold or pain tolerance after chronic opioid exposure (Martinez and Fletcher, 2012). Pain threshold is the lowest intensity of stimulation at which pain is experienced, and pain tolerance is the amount of pain from a given stimulus a person can handle before seeking relief.

Opioid-induced hyperalgesia often is confused with opioid tolerance because of the manifestations of similar symptoms. AOT is defined as an increase in the dose required maintaining adequate analgesia in patients receiving opioid medication for the treatment of pain in clinical settings (Angst and Clark, 2006; Chu et al., 2008). Clinical data indicates that early postoperative pain scores and subsequent greater demand of opioids could be attributed to tolerance, while the greater requirement for opioids at a later recovery stage could be associated with OIH after high-dose remifentanil anesthesia.

**GENERAL CONSENSUS OF AOT AND OIH**

Recently, many studies have focused on the development of AOT and OIH after using opioids based on idea that OIH might be a potential risk factor for the development of chronic pain after surgery (Perkins and Kehlet, 2000; Woolf and Salter, 2000; Wilder-Smith and Arendt-Nielsen, 2006). The circumstances under which OIH may occur are also not yet entirely understood but may include high doses, long-term treatment, or abrupt changes in concentrations (Simonnet and Rivat, 2003). Most authors have suggested that the higher dose of opioids induce the higher tolerance and/or hyperalgesia. OIH was observed either to follow analgesia and lasted long after opioid exposure ended (Celerier et al., 2000; Kissin et al., 2000; Li et al., 2001), or during continuous opioid exposure (Laulin et al., 1999; Vanderah et al., 2000). It has been reported that high intraoperative doses of opioids not only increase postoperative pain scores and acute morphine consumption, but also induce significant nociceptive threshold changes (Chia et al., 1999; Guignard et al., 2000; Mao, 2002; Angst et al., 2003; Joly et al., 2005; Van Elstraete et al., 2005; Cabanero et al., 2009). Celerier et al. (2000) showed that fentanyl injection was associated with sustained lowering of the nociceptive threshold below baseline value, and the higher the fentanyl dose used, the more pronounced was the fentanyl-induced hyperalgesia. Laulin et al. (1999) reported that repeated once-daily heroin injections induced a gradual lowering of the nociceptive threshold which progressively masked a sustained heroin analgesic functional effect, which is suggested as opiate tolerance.

If all types of opioids have been shown to induce such a dose-dependent hypersensitivity, exposure to short-acting opioids, such as remifentanil, seems more likely to be responsible for postoperative high pain scores, high morphine consumption, and hypersensitivity to pain (Guignard et al., 2000; Angst et al., 2003; Hood et al., 2003; Koppert et al., 2003a). A relatively large-dose of intraoperative remifentanil has been shown to induce postoperative hyperalgesia more rapidly and more frequently as compared with longer-acting opioids (Derrode et al., 2003; Joly et al., 2005; Koppert and Schmelz, 2007). These results are in agreement with the clinical observation of increased postoperative pain and morphine requirement (Zarate et al., 1999; Guignard et al., 2000, 2002).

As many papers suggest, remifentanil could induce AOT and/or OIH (Vinik and Kissin, 1998; Hayashida et al., 2003; Gomez de Segura et al., 2009; Aguado et al., 2011). Many authors documented that remifentanil CI alone induced AOT in the dose-dependent manner within first few hours in animal models (Hayashida et al., 2003; Aguado et al., 2011). A study in healthy human volunteers performed by Vinik and Kissin (1998) also suggested that AOT was profound and developed very rapidly, and remifentanil of 0.1 μg/kg/min resulted in the maximum analgesic effect in 60–90 min, and then began to decline despite the constant-rate infusion, eventually reaching 1/4 of the peak value after 3 h of infusion, measuring by cold thermal and mechanical noxious stimulation (Vinik and Kissin, 1998).

A small number of clinical studies have looked at AOT and OIH in the setting of acute perioperative opioid exposure. A series
of studies in patients undergoing surgery suggested that exposure to a high rather than to a low intraoperative opioid dose was associated with the increased opioid consumption and/or pain in the postoperative period (Cooper et al., 1997; Chia et al., 1999; Guignard et al., 2000; Joly et al., 2005). A feasible explanation for these findings is either the development of acute tolerance on the rescue opioids for controlling the postoperative pain or a possible OIH in patients exposed to a high intraoperative opioid dose (Angst and Clark, 2006). Guignard et al. (2000) suggested that AOT as well as OIH might be induced by the acute exposure to large doses of opioids. The patients received 0.3 ± 0.2 μg/kg/min of the intraoperative remifentanil required morphine significantly earlier and needed nearly twice more morphine in the first 24 postoperative hours than those who remifentanil was kept constant at 0.1 μg/kg/min. Furthermore, despite higher morphine requirement, higher pain scores were observed in group that remifentanil was infused higher. Joly et al. (2005), in their randomized, double-blind study, showed that intraoperative remifentanil of 0.4 μg/kg/min triggered the larger hyperalgesia as well as the larger morphine consumption for 48 postoperative hours, compared with remifentanil of 0.05 μg/kg/min. In prospective, randomized, double-blind study, they suggested that remifentanil of mean 0.28 μg/kg/min was associated with the development of clinically relevant AOT, in patients underwent the general anesthesia using propofol infusion (Crawford et al., 2006).

Many authors showed that the OIH can develop differently for different types of pain such as transdermal electrical stimulation (Angst et al., 2003; Hood et al., 2003; Koppert et al., 2003a,b; Troster et al., 2006), cold pressor pain (Compton et al., 2003, 2004), and pressure-evoked pain (Luginbuhl et al., 2003). Transdermal electrical stimulation used for inducing mechanical hyperalgesia on an experimental skin lesion rendered hyperalgesia in human volunteers. These investigators suggested that 30–90 min of remifentanil exposure significantly enlarge the skin area with pre-existing mechanical hyperalgesia by transdermal electrical stimulation with direct relation of the infusion duration and the opioid dose (Angst et al., 2003; Hood et al., 2003; Koppert et al., 2003a,b; Troster et al., 2006). This hyperalgesia was sustained up to 4 h after stopping infusion (Hood et al., 2003). They also documented that the pain score was increased and the pain threshold was decrease, by dose-dependent manner, after the discontinuation of opioids (Angst et al., 2003; Hood et al., 2003; Koppert et al., 2003a). In a model of acute physical opioid dependence, which withdrawal was precipitated with the opioid antagonist naloxone after a single injection of opioid (Compton et al., 2003, 2004), the authors showed that sensitivity to cold pressor pain was significantly increased after injection of naloxone and OIH may be triggered if opioid effect is suddenly disappeared or reversed. Finally, Luginbuhl et al. (2003) suggested that remifentanil alone induced significant hyperalgesia detected by test for pressure pain tolerance threshold in volunteers.

**SUGGESTED DOESES OF REMIFENTANIL INDUCING AOT AND OIH**

Most articles documented that AOT and OIH were induced during and after remifentanil infusion at ≥0.1 μg/kg/min (Vinik and Kissin, 1998; Glass et al., 1999; Guignard et al., 2000; Gustorff et al., 2002; Angst et al., 2003; Koppert et al., 2003a; Joly et al., 2005; Angst et al., 2009; Cabanero et al., 2009). In a mouse model, they suggested that remifentanil-induced hyperalgesia was induced by dose-dependent manner and the calculated ED50s for thermal and mechanical hyperalgesia was 1.7 (95% confidence interval, 1.3–2.1) and 1.26 (1.0–1.6) μg/kg/min, respectively (Cabanero et al., 2009). Infusion of remifentanil at a rate of 0.1 μg/kg/min induced the very rapid and profound acute tolerance during infusion (Vinik and Kissin, 1998; Glass et al., 1999), while a rate of 0.08 μg/kg/min could not induce acute tolerance in the cold pressor test and in models of electrical and heat pain (Gustorff et al., 2002). Angst et al. (2003) showed that pre-existing mechanical hyperalgesia was significantly aggravated after discontinuation of remifentanil at a rate of 0.10 μg/kg/min. Koppert et al. (2003a) also suggested that even though remifentanil dose-dependently reduced pain and mechanical hyperalgesia during the infusion, after discontinuation of infusion, pain and mechanical hyperalgesia increased significantly in group which was administered remifentanil at a rate of 0.10 μg/kg/min compared with at a rate of 0.05 μg/kg/min. Furthermore, in the patients receiving higher intraoperative remifentanil, such as 0.3 ± 0.2 and 0.4 μg/kg/min, than 0.10 μg/kg/min, the time of first morphine requirement was significantly earlier and the morphine consumption in the first 24 or 48 postoperative hour was significantly larger, which suggest that remifentanil causes AOT and hyperalgesia (Guignard et al., 2000; Joly et al., 2005). Therefore, AOT as well as OIH might be induced by the acute exposure to large doses of opioids.

In studies on AOT and OIH, while most authors have used the CI mode, there are a few reports using the target-controlled infusion (TCI) mode (Hood et al., 2003; Angst et al., 2009; Shin et al., 2010; Richebe et al., 2011). Hood et al. (2003) showed that areas of hyperalgesia continuously enlarged 4 h after remifentanil (targeted concentration of 3.1 ± 1.2 ng/ml) was stopped, to 180% ± 47%. Shin et al. (2010) suggested that remifentanil using TCI at 4 ng/ml induced the more increased cumulative morphine consumption and postoperative hyperalgesia than that at 1 ng/ml during sevorflurane anesthesia. This result is similar with that of previous studies using CI mode; higher dose of opioid, higher development of AOT and OIH. The infusion rate for remifentanil 0.1 μg/kg/min can achieve a stable plasma concentration between 2.7 and 2.9 mg/ml during the infusion (Angst et al., 2003). A bolus of remifentanil 1 μg/kg followed by infusion 0.2 μg/kg/min will produce stable plasma concentrations of 4–5 ng/ml within a few minutes (Minto et al., 1997). Angst et al. (2009) documented that target remifentanil concentrations corresponding to infusion rates of 0.065 and 1.3 μg/kg/min did not induce tolerance in any of their pain models. Remifentanil concentrations of 1.6 and 3.2 ng/ml, which are commonly used in a clinical setting to provide analgesia during surgery, correspond to steady-state concentrations achieved when infusing remifentanil at a constant rate of about 0.065 and 0.13 μg/kg/min (Glass et al., 1999). Therefore, according these references, ≥0.1 μg/kg/min using CI mode and ≥2.7 ng/ml using TCI mode seem to be sufficient to develop hyperalgesia.
CONTROVERSIAL RESULTS ON DEVELOPMENT OF AOT AND OIH BY REMIFENTANIL

There is controversial results on AOT and OIH induced by remifentanil at the perioperative period, even though many authors suggested that remifentanil could induce them (Schraag et al., 1999; Cortinez et al., 2001; Hansen et al., 2005; Lahtinen et al., 2008; Angst et al., 2009; Yeom et al., 2012). Angst et al. (2009) documented that 3 h infusion of remifentanil of up to 4.0 ng/ml was not associated with the development of significant tolerance to analgesic in placebo-controlled, double-blind study. Cortinez et al. (2001) also suggested that remifentanil-based anesthesia (0.23 μg/kg/min, average duration; 116 min) did not induce the AOT when compared with sevoflurane-based anesthesia in patients undergoing elective gynecologic surgery. Hansen et al. (2005) investigated how remifentanil of 0.4 μg/kg/min intra-operatively affected post-operative pain and opioid consumption after major abdominal surgery. In a double-blind study, although they found higher visual analog scale score in the remifentanil group compared with placebo during the immediate postoperative period, this difference was no longer significant 2 h after surgery or during the remainder of the 24-h observation period. A prospective, randomized, double-blind study, showed that 3 h infusion of remifentanil of 0.3 μg/kg/min did not increase postoperative pain or opioid consumption in cardiac surgery patients who underwent sufentanil/propofol-based general anesthesia (Lahtinen et al., 2008). Yeom et al. (2012) suggested that remifentanil did not appear to cause AOT and OIH in patients undergoing spinal fusion even though there was significant differences in the mean intraoperative infusion rate of remifentanil (0.16 μg/kg/min vs. 0.03 μg/kg/min) for a short period of time (averaging 225 and 216 min, respectively). Schraag et al. (1999) found that Remifentanil infusion using specially designed patient-maintained TCI systems, which was controlled according to the patients demand for postoperative pain control by up-and-down method (intervals 0.2 ng/ml) did not show any evidence of rapid development of acute tolerance in patients maintained hypnotic dose of remifentanil in the first six postoperative hours from end of total intravenous anesthesia with remifentanil and propofol.

FACTORS THAT LEAD TO DISCREPANCIES REGARDING AOT AND OIH

The clinical relevance of above mentioned results is questionable and there is some limitation in negative results concerning AOT and OIH. These discrepancies can be explained by multiple methodological issues including the administrated dose and duration of opioids administration, the different infusion mode, the co-administrated anesthetic drug’s effect, method assessing pain sensitivity, and the repetitive and potentially tissue damaging nature of the stimuli used to determine the threshold during opioid infusion (Angst and Clark, 2006; Lahtinen et al., 2008; Fishbain et al., 2009; Simonnet, 2009).

First, we can explain these discrepant results by differences in exposed opioid doses and administration duration. Studies reporting positive results have shown that AOT develops in dose-dependent fashion and only becomes evident when total opioid exposure is quite high. The non-significant increase of postoperative pain and opioid consumption in studies reporting negative results may be noticed because of lower total intraoperative opioid exposure when compared with the positive results, suggesting a dose-dependent effect of opioids on the development of OIH (Guignard et al., 2000; Cortinez et al., 2001; Lee et al., 2005). Cabanero et al. (2009) agreed that remifentanil induced dose-dependent pronociceptive effects for thermal and mechanical hyperalgesia, which lasted longer with higher doses, but they suggested that the duration of infusion did not alter the pronociceptive effects of remifentanil. This negative result might be explained by the shorter exposed duration, just over 30 or 60 min, than the positive results studies, in which Acute tolerance is typically investigated during CI over 2–3 h, whereas hyperalgesia is usually assessed within 1 h post-infusion (Guignard et al., 2000, 2002; Laulin et al., 2002; Hayashida et al., 2003; Gomez de Segura et al., 2009; Benito et al., 2010; Aguado et al., 2011; Ishida et al., 2012; Ishii et al., 2013). In the recent animal study, they showed that intravenous remifentanil infusion alone induced transient hyperalgesia associated with the duration of exposure to remifentanil (Ishida et al., 2012). While 30 min remifentanil infusion did not induce hyperalgesia, 120 min remifentanil infusion induced the hyperalgesia regardless of dose. However, hyperalgesia was not sustained more than 60 min. Other study also documented that remifentanil-induced hyperalgesia started from 2 h after surgery and reached its peak at 24–48 h after surgery (Gu et al., 2009).

Also, it is not sufficient to explain the cause of these discrepancies by using the dose and duration of remifentanil infusion. Some authors have reported the negative results even though they used remifentanil infusion rate that was enough to develop hyperalgesia. It can be partially explained by the effect of co-administered anesthetic drugs, such as propofol, sevoflurane and nitrous oxide. Fodale et al. (2006) suggested that AOT was not induced when remifentanil was co-administered with propofol or sevoflurane, which produced an inhibiting effect at NMDA receptors neutralizing the remifentanil stimulation on these receptors. However, Solt et al. (2006) documented that sevoflurane has only a minimal inhibitory effect on NMDA receptors, which are considered to be involved in the development of opioid-related hypersensitivity (Tomkins and Campbell, 2011). Relatively low sevoflurane concentrations (1.0%) reverse OIH, but there was the lack of effect of sevoflurane concentrations of 1.0 and 1.5% to oppose hyperalgesia following high-dose opioids (Solt et al., 2006; Richebe et al., 2009). Shin et al. (2010) also suggested that remifentanil-induced hyperalgesia was not apparent during propofol anesthesia compared with the effect produced during sevoflurane anesthesia even though dosage of remifentanil was increased from 1.0 to 4.0 ng/ml. This result can be supported by that propofol may have some modulatory effect on OIH, through inhibition of the NMDA subtype of the glutamate receptor (Orser et al., 1995; Kingston et al., 2006), which is one of the potential mechanisms that induced the OIH, and possibly through interactions with gamma-aminobutyric acid (GABA-A) receptors at the supraspinal level (Wang et al., 2004; Singler et al., 2007). Specifically, sub-hypnotic dose of propofol has analgesic effects, which delayed the onset of anti-algesia after remifentanil infusion (Singler et al., 2007). However, the clinical significance of
these findings, especially in higher dosages used in the intraoperative setting, remains to be studied. In addition, some authors ignored the impact that nitrous oxide might have against the AOT and hyperalgesia (Cortinez et al., 2001; Yeom et al., 2012). Echevarria et al. (2011) reported that the group using the 70% nitrous oxide with remifentanil of 0.3 μg/kg/min showed a greater decreased mechanical threshold than the group without nitrous oxide at postoperative 12–18 h, even though the postoperative pain scores and cumulative morphine consumption was similar between the groups. Lee et al. (2005) suggested that 70% nitrous oxide showed comparable effect on the postoperative opioid consumption similar to remifentanil at mean 0.17 μg/kg/min.

Next, different infusion mode also can influence the development of AOT and OIH even though they have an equipotential effect on the pain control. TCI has been shown not only to improve intraoperative hemodynamic stability but also to decrease intraoperative remifentanil requirements (Minto et al., 1997; De Castro et al., 2003). Interestingly, Richebe et al. (2011) evaluated whether the use of TCI mode also would lead to decrease in early postoperative period hyperalgesia after cardiac surgery. They suggested that an infusion of intraoperative remifentanil using TCI mode (7 ng/ml) reduced postoperative hyperalgesia, compared with that using CI mode (0.3 μg/kg/min), and this decrease in postoperative hyperalgesia was sustained and lasted throughout the 1st postoperative week. The conclusion of the study was supported by the difference of intraoperative infused total remifentanil dose, which was greater in CI than in TCI group.

Then, the possibility of cumulative tissue injury manifesting as AOT or OIH should be carefully excluded (Petrenko et al., 2012). Especially, this is likely to occur with repetitive testing protocols in a situation in which protective withdrawal reflexes are impaired or abolished by opioid administration. In Luginbuhl et al.’s (2003) study, they exposed volunteers to significantly higher nociceptive input during remifentanil vs. during saline placebo administration. It cannot be excluded that postinfusion hyperalgesia resulted from more intense noxious stimulation during the remifentanil infusion rather than the opioid administration itself. On the other hand, Ishii et al. (2013) documented that neither acute tolerance nor hyperalgesia was observed even in the setting when they used a tapered remifentanil infusion to rapidly attain maximum analgesic effect of remifentanil and tried to minimize the repetitive and potentially tissue damaging nature of the stimuli.

Finally, it might contribute to influence of development of OIH, in studies exposing patients to high intraoperative opioid doses, whether assessment of pain sensitivity before and after surgery was formally done or not. No causal relationship between acute perioperative opioid exposure and development of OIH can be established without direct measurement of pain sensitivity. If patients have a comorbidity affecting sensory thresholds preoperatively, this condition could distort postoperative measures on OIH. The German Network on Neuropathic Pain established a standardized quantitative sensory testing (QST) protocol to investigate the somatosensory thresholds in healthy subjects and in patients with neuropathic pain (Rolke et al., 2006). Reference values from healthy subjects could be used to establish normal sensory functioning in patients before anesthesia. In a clinical setting, this direct measure could be used for distinguishing between OIH and AOT, because of clinical importance, as AOT can be overcome by dose increase, while OIH may be aggravated by the same intervention. Without direct measures to assess hyperalgesia such as QST, the results are not easy to distinguish from acute tolerance (Vinik and Kissin, 1998). Clinical studies examining remifentanil-induced hyperalgesia by QST showed that, at a relatively high dose, remifentanil decreased the pain threshold (Gustorff et al., 2002; Joly et al., 2005; Schmidt et al., 2007; Song et al., 2011; Yalcin et al., 2012). These studies used remifentanil infusions at clinically standard rates, and all of them showed clear hyperalgesia either shortly after discontinuing infusion or 1 and 2 days postoperatively. However, most studies confirmed the reality of this phenomenon using indirect evidences, such as greater postoperative pain and morphine consumptions instead of using QST (Guignard et al., 2000; Rauf et al., 2005). Treskatsch et al. (2014) did not demonstrate any influence on clinical outcome parameters of pain after remifentanil of >0.2 μg/kg/min, and they suggested that indirect evidences might be less sensitive to detect OIH compared with QST. Therefore, we think that a further study is needed to reveal the development of AOT and OIH using QST.

**IMPORTANCE OF AOT AND/OR OIH IN CONSIDERING THE REDUCTION OF REMIFENTANIL DOSAGE AND ADOPTING PREVENTIVE MODULATIONS**

Forty-one percentage of all surgical patients still experience moderate to severe acute postoperative pain and that 24% experience inadequate pain relief (Dolin et al., 2002). It has recently been highlighted that chronic pain as a direct result of surgery is more common than previously recognized (Perkins and Kehlet, 2000). Furthermore, in cohort study on postoperative remifentanil-induced hyperalgesia, its incidence was reported 16.1% of patients undergoing general anesthesia with remifentanil (Ma et al., 2011). Hyperalgesia and increased pain in the postoperative period is now considered a major candidate mechanism for the development of chronic pain (Perkins and Kehlet, 2000; Woolf and Salter, 2000; Wilder-Smith and Arendt-Nielsen, 2006). Therefore, less postoperative hyperalgesia results in better acute postoperative pain control (Joly et al., 2005), and interventions associated with alterations of postoperative hyperalgesia are also associated with changes in acute postoperative pain outcomes (Guignard et al., 2000; Rauf et al., 2005).

However, there is a lack of good quality clinical research in this area, despite the fairly extensive basic science evidence. In a structured evidence-based review for all levels of evidence on OIH in humans (Fishbain et al., 2009), they suggested that there was not sufficient evidence to support or refute the existence of OIH in humans except in the case of normal volunteers receiving opioid infusions. There was consistent evidence that opioid infusion in normal volunteers induced either an increase in secondary hyperalgesia or allodynia, and there was inconsistent evidence on pain threshold and tolerance in normal volunteers or chronic pain patients although the threshold decreased with opioid infusion. They also documented that using of opioid in
perioperative period increased the postoperative pain or opioid requirements with inconsistent evidence. In other recent evidence based systematic review (Rivosecchi et al., 2014), they suggested that remifentanil might induce a degree of hyperalgesia, but it did not reach a level of clinical significance that requires prevention.

There are some questions regarding the importance of the drug use to prevent AOT and OIH in postoperative patients and whether the assessment of OIH at immediate postoperative period is suitable. Clinical studies assessing the preventive effect of drugs on OIH in the immediate postoperative period, showed that the clinical benefit is either absent (Echevarria et al., 2011), limited to a moderate opioid-sparing effect (Joly et al., 2005; Shin et al., 2010), or a slight reduction in pain scores (Shin et al., 2010; Song et al., 2011). According to these results, Martinez and Fletcher (2012) suggested that the immediate postoperative period may not be the optimal period to detect the preventive effects on OIH, even though additional clinical data need to confirm it.

Furthermore, Simonnet and Rivat (2003) suggested that OIH should be considered as a normal adaptive response countering the perturbations caused by administration of analgesic opioids. However, it is tempting to speculate that the long lasting hyperalgesia induced by endogenous or exogenous opioids may still facilitate learning processes and memorization of drives so that environmental changes which might lead to pain may be better avoided. From a medical viewpoint, OIH following a first opioid administration is not a passive response but it might be considered as the first step of an active process leading to pain sensitization. This suggests that opioids have reinforced a nociceptive memory which could contribute to pain chronicization.

CONCLUSION

Current experimental and clinical data generally support the development of AOT and OIH in specific settings such as acute remifentanil exposure in human volunteer and postsurgical pain cohorts when remifentanil was infused at \( \geq 0.1 \mu g/kg/min \) either alone or with inhalation anesthetics. Therefore, in these situations, clinicians need to be cautious for the possibility of the development of AOT and OIH, which may impair treatment of pain or even aggravate preexisting pain. Clinicians should suspect manifestation of OIH when opioid treatment effect seems to decline in the absence of disease progression, with unexplained pain reports or allodynia unassociated with the site of injury. According to the previous reported results, co-administered anesthetic drugs, such as propofol and nitrous oxide, and using of TCI model seem to be helpful to modulate the development of the AOT and OIH. However, there are not sufficient data to support the evidence of modulatory effect of them. Finally, we also cannot find any strong consistent evidence to support the need to reduce the dose of remifentanil or apply the modalities for preventing the AOT and the OIH. Consequently, further studies will need to investigate whether remifentanil induce the AOT and the OIH after general anesthesia using propofol, nitrous oxide, or TCI mode through high quality prospective trials. And the development of the AOT and the OIH should be evaluated with direct measures such as QST. It is also important to investigate if remifentanil-induced hyperalgesia may contribute to the development of chronic pain, and if this contribution can be attenuated or even reversed through pharmacologic modulation.

ACKNOWLEDGMENTS

This study was supported by research fund from Chosun University, 2011 and in collaboration with Ohio State University Wexner Medical Center, Department of Anesthesiology, Division of Neuroanesthesia.

REFERENCES

Aguado, D., Abreu, M., Benito, J., Garcia-Fernandez, J., and Gomez De Segura, I. A. (2011). Ketamine and remifentanil interactions on the sevoflurane minimum alveolar concentration and acute opioid tolerance in the rat. Anesth. Analg. 113, 305–312. doi: 10.1213/ANE.0b013e31827517a

Angst, M. S., Chu, L. F., Tingle, M. S., Shafer, S. L., Clark, J. D., and Drover, D. R. (2009). No evidence for the development of acute tolerance to analgesia, respiratory depressant and sedative opioid effects in humans. Pain 142, 17–26. doi: 10.1016/j.pain.2008.11.001

Angst, M. S., and Clark, J. D. (2006). Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104, 570–587. doi: 10.1097/00000542-200603000-00025

Angst, M. S., Koppert, W., Pahl, I., Clark, D. J., and Schmelz, M. (2003). Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 106, 49–57. doi: 10.1016/S0304-3959(03)00276-8

Benito, J., Aguado, D., Abreu, M. B., Garcia-Fernandez, J., and Gomez De Segura, I. A. (2010). Remifentanil and cyclooxygenase inhibitors interactions in the minimum alveolar concentration of sevoflurane in the rat. Br. J. Anaesth. 105, 810–817. doi: 10.1093/bja/eqq241

Bowlde, T. A., Camporesi, E. M., Maysick, L., Hogue, C. W. Jr., Miguel, R. V., Pitts, M., et al. (1996). A multicenter evaluation of remifentanil for early postoperative analgesia. Anesth. Analg. 83, 1292–1297. doi: 10.1097/00000539-199612000-00006

Bowlde, T. A., Ready, L. B., Kharasch, E. D., Nichols, W. W., and Cox, K. (1997). Transition to post-operative epidural or patient-controlled intravenous analgesia following total intravenous anaesthesia with remifentanil and propofol for abdominal surgery. Eur. J. Anaesthesiol. 14, 374–379. doi: 10.1002/1970070000-0006

Burkine, H., Dunbar, S., and Van Aken, H. (1996). Remifentanil: a novel, short-acting, mu-opioid. Anesth. Analg. 83, 646–651. doi: 10.1097/00000542-199609000-00038

Cabanero, D., Campillo, A., Celerier, E., Romero, A., and Puig, M. M. (2000). Pronociceptive effects of remifentanil in a mouse model of postsurgical pain: effect of a second surgery. Anesthesiology 111, 1334–1345. doi: 10.1097/01.ANJ.0b013e3181bf6b61

Celerier, E., Rivat, C., Jun, Y., Laulin, J. P., Larcher, A., Reynier, P., et al. (2000). Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine. Anesthesiology 92, 465–472. doi: 10.1097/00000542-200002000-00009

Cha, Y. Y., Lin, K., Wang, J. J., Kuo, M. C., and Ho, S. T. (1999). Intraoperative high dose fentanyl induces postoperative fentanyl tolerance. Can. J. Anaesth. 46, 872–877. doi: 10.1007/BF03012978

Chu, L. F., Angst, M. S., and Clark, D. (2008). Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin. J. Pain 24, 479–496. doi: 10.1097/AJP.0b013e31816b2f43

Compton, P., Athanasos, P., and Elashoff, D. (2003). Withdrawal hyperalgesia after acute opioid physical dependence in nonaddicted humans: a preliminary study. J. Pain 4, 511–519. doi: 10.1016/j.jpain.2003.08.003

Compton, P., Mirotto, K., and Elashoff, D. (2004). Precipitated opioid withdrawal across acute physical dependence induction methods. Pharmacol. Biochem. Behav. 77, 263–268. doi: 10.1016/j.pbb.2003.10.017

Cooper, D. W., Lindsay, S. L., Ryall, D. M., Kokri, M. S., Eldabe, S. S., and Lear, G. A. (1997). Does intrathecal fentanyl produce acute cross-tolerance to i.v. morphine? Br. J. Anaesth. 78, 311–313. doi: 10.1093/bja/78.3.311
Kim et al.  Opioid induced hyperalgesia of remifentanil

Hayashida, M., Fukunaga, A., and Hanaoka, K. (2003). Detection of acute tolerance to the analgesic and nonanalgetic effects of remifentanil infusion in a rabbit model. *Anesth. Analg. 97*, 1347–1352. doi: 10.1213/01.ANE.0000083730.80416.38

Hood, D. D., Curry, R., and Eisenach, J. C. (2003). Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. *Anesth. Analg. 97*, 810–815. doi: 10.1213/01.ANE.0000078481.80093.88

Hughes, M. A., Glass, P. S., and Jacobs, J. R. (1992). Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. *Anesthesiology 76*, 334–341. doi: 10.1097/00000542-199203000-00003

Ishida, R., Nikai, T., Hashimoto, T., Tsumori, T., and Saito, Y. (2012). Intravenous infusion of remifentanil induces transient withdrawal hyperalgesia depending on administration duration in rats. *Anesth. Analg. 114*, 224–229. doi: 10.1213/ANE.0b013e3182376787

Ishii, H., Pettenko, A. B., Kohno, T., and Baba, H. (2013). No evidence for the development of acute analgesic tolerance during and hyperalgesia after prolonged remifentanil administration in mice. *Mol. Pain 9*, 11. doi: 10.1186/1744-0689-9-11

Joly, V., Riche, P., Guignard, B., Fletcher, D., Maurette, P., Sessler, D. I., et al. (2005). Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. *Anesthesiology 103*, 147–155. doi: 10.1097/00000542-200507000-00025

Kapila, A., Glass, P. S., Jacobs, J. R., Muir, K. T., Hermann, D. J., Shi-raishi, M., et al. (1995). Measured context-sensitive half-times of remifentanil and alfentanil. *Anesthesiology 83*, 968–975. doi: 10.1097/00000542-199511000-00009

Kingston, S., Mao, L., Yang, L., Arora, A., Fibuch, E. E., and Wang, J. Q. (2006). Propofol inhibits phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in neurons. *Anesthesiology 104*, 763–769. doi: 10.1097/00000542-200604000-00021

Kissin, J., Bright, C. A., and Bradley, E. L. Ir. (2000). The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations? *Anesth. Analg. 91*, 1483–1488. doi: 10.1097/00000539-200120000-00003

Koppert, W., Angst, M., Alsheimer, M., Sittl, R., Albrecht, S., Schuttler, J., et al. (2003a). Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. *Pain 106*, 91–99. doi: 10.1016/S0304-3959(03)00294-X

Koppert, W., Sittl, R., Scheuber, K., Alsheimer, M., Schmelz, M., and Schuttler, J. (2003b). Differential modulation of remifentanil-induced analgesia and postin- fusion hyperalgesia by S-ketamine and clonidine in humans. *Anesthesiology 99*, 152–159. doi: 10.1097/00000542-200307000-00025

Koppert, W., and Schmelz, M. (2007). The impact of opioid-induced hyperalgesia for postoperative pain. *Best Pract. Res. Clin. Anaesthesiol. 21*, 65–83. doi: 10.1016/j.bpa.2006.12.004

Lahtinen, P., Kokki, H., and Hynynen, M. (2008). Remifentanil infusion does not induce opioid tolerance after cardiac surgery. *J. Cardiothorac. Vasc. Anesth. 22*, 225–229. doi: 10.1053/j.jvca.2007.07.004

Laulin, J. P., Celerier, E., Larcher, A., Le Moal, M., and Simonnet, G. (1999). Opiate tolerance to daily heroin administration: an apparent phenomenon associated with enhanced pain sensitivity. *Neuroscience 89*, 631–636. doi: 10.1016/S0306-4522(98)00652-6

Laulin, J. P., Maurette, P., Corcuff, J. B., Rivat, C., Chauvin, M., and Simonnet, G. (2002). The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. *Anesth. Analg. 94*, 1263–1269. doi: 10.1213/01.ANE.00000539-200205000-00040

Lee, L. H., Irwin, M. G., and Liu, S. K. (2005). Intraoperative remifentanil infusion does not increase postoperative opioid consumption compared with 70% nitrous oxide. *Anesthesiology 102*, 398–402. doi: 10.1097/00000542-200502000-00024

Li, X., Angst, M. S., and Clark, J. D. (2001). Opioid-induced hyperalgesia and incisional pain. *Anesth. Analg. 93*, 204–209. doi: 10.1097/01.ANE.0000048086.58161.18

Kissin, I., Bright, C. A., and Bradley, E. L. Jr. (2000). The effect of ketamine on acute tolerance to remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. *Anesthesiology 92*, 398–402. doi: 10.1097/01.ANE.0000048086.58161.18
Ma, J. F., Huang, Z. L., Li, J., Hu, S. J., and Lian, Q. Q. (2011). Cohort study of remifentanil-induced hyperalgesia in postoperative patients. Zhonghua Yi Xue Za Zhi 91, 977–979.

Mao, J. (2002). Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 100, 213–217. doi: 10.1016/S0304-3959(02)00422-0

Martinez, V., and Fletcher, D. (2012). Prevention of opioid-induced hyperalgesia in surgical patients: does it really matter? Br. J. Anaesth. 109, 302–304. doi: 10.1093/bja/aeq278

McAtamney, D., O’Hare, R., Hughes, D., Carabine, U., and Mirakhur, R. (1998). Evaluation of remifentanil for control of haemodynamic response to tracheal intubation. Anaesthesia 53, 1223–1227. doi: 10.1093/ane.100.10.1139

Minto, C. F., Schnider, T. W., Egan, T. D., Youngs, E., Lemmens, H. J., and Lahm, C. B. (1997). Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development. Anesthesiology 86, 10–23. doi: 10.1097/00000542-199701000-00004

O’Hare, R., McAtamney, D., Mirakhur, R. K., Hughes, D., and Carabine, U. (1999). Bolus dose remifentanil for control of haemodynamic response to tracheal intubation during rapid sequence induction of anaesthesia. Br. J. Anaesth. 82, 283–285. doi: 10.1093/bja/82.2.283

Orser, B. A., Bertlik, M., Wang, L. Y., and Macdonald, J. F. (1995). Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurones. Br. J. Pharmacol. 116, 1761–1768. doi: 10.1111/j.1476-5381.1995.tb16660.x

Perkins, F. M., and Kehlet, H. (2000). Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology 93, 1123–1133. doi: 10.1097/00000542-200010000-00038

Petrenko, A. B., Ishii, H., Kohno, T., and Lian, Q. Q. (2011). Maintenance anaesthetics during remifentanil-based anaesthesia might affect postoperative care following breast cancer surgery. Br. J. Anaesth. 105, 661–667. doi: 10.1093/bja/aep257

Simonnet, G. (2009). Acute tolerance to opioids: methodological, theoretical and clinical implications. Pain 142, 3–4. doi: 10.1016/j.pain.2009.01.004

Simonnet, G., and Rivat, C. (2003). Opioid-induced hyperalgesia: abnormal or normal pain? Neuroreport 14, 1–7. doi: 10.1097/00001055-1999051340.96524.e7

Singh, H., Vichitvejjaisal, P., Gaines, G. Y., and White, P. F. (1995). Comparative effects of lidocaine, esmolol, and nitroglycerin in modifying the hemodynamic response to laryngoscopy and intubation. J. Clin. Anesth. 7, 5–8. doi: 10.1016/0952-8188(94)90013-T

Singler, B., Troster, A., Manering, N., Schuttler, J., and Koppert, W. (2007). Modulation of remifentanil-induced postinfusion hyperalgesia by propofol. Anesth. Analg. 104, 1397–1403. doi: 10.1213/ane.0b013e318263ca5c

Sneyd, J. R., Camu, F., Doenicke, A., Mann, C., Holgersen, O., Helmers, J. H., et al. (2001). Remifentanil and fentanyl during anaesthesia for major abdominal and gynaecological surgery. An open, comparative study of safety and efficacy. Eur. J. Anaesthesiol. 18, 605–614. doi: 10.1002/eja.110003643-

Solt, K., Eger, E. I. II, and Raines, D. E. (2006). Differential modulation of human N-methyl-D-aspartate receptors by structurally diverse general anesthetics. Anesth. Analg. 102, 1407–1411. doi: 10.1213/01.ANE.0000204252.22324.b3

Song, J. W., Lee, Y. W., Yoon, K. B., Park, S. J., and Shim, Y. H. (2011). Magnesium sulfate prevents remifentanil-induced postoperative hyperalgesia in patients undergoing thyroidectomy. Anesth. Analg. 113, 390–397. doi: 10.1213/ane.0b013e31821d72bc

Tompkins, D. A., and Campbell, C. M. (2011). Opioid-induced hyperalgesia: clinically relevant or extraneous research phenomenon? Curr. Pain Headache Rep. 15, 129–136. doi: 10.1007/s11611-010-0171-1

Treskatsch, S., Klambek, M., Mousa, S. A., Kopf, A., and Schäfer, M. (2014). Influence of high-dose intraoperative remifentanil with or without amantadine on postoperative pain intensity and morphine consumption in major abdominal surgery patients: a randomised trial. Eur. J. Anaesthesiol. 31, 41–49 doi: 10.1097/EJA.0000434967.00003790.0c

Troster, A., Sittit, R., Singler, B., Schmelz, M., Schuttler, J., and Koppert, W. (2006). Remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans. Anesthesiology 105, 1016–1023. doi: 10.1097/00000542-200611000-00024

Vanderah, T. W., Gardell, L. R., Burgess, S. E., Ibrahim, M., Dogrul, A., Zhong, C. M., et al. (2000). Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J. Neurosci. 20, 7074–7079.

Van Elstraete, A. C., Sitbon, P., Trabold, F., Mazoit, J. X., and Benhadou, D. (2005). A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: the protective effect of prior administration of ketamine. Anesth. Analg. 101, 1750–1756. doi: 10.1213/01.ANE.0000184136.20929.7f

Vink, H. R., and Kissin, I. (1998). Rapid development of tolerance to analgesia during remifentanil infusion in humans. Anesth. Analg. 86, 1307–1311.

Wang, Y., Cao, J. L., Zeng, Y. M., and Dai, T. J. (2004). GABAA receptor partially mediates morphine-induced hyperalgesia and preoperative hyperalgesia by means of hyperalgesia in patients undergoing gynaecological surgery. An open, comparative study of safety and efficacy. Eur. J. Anaesthesiol. 18, 605–614. doi: 10.1002/eja.110003643-

Woolf, C. J., and Salter, M. W. (2000). Neuronal plasticity: increasing the gain in pain. Science 288, 1765–1769. doi: 10.1126/science.288.5472.1765

Yalcin, N., Uzun, S. T., Reisli, R., Borazan, H., and Otelcioglu, S. (2012). A single dose of intrathecal morphine in rats induces long-lasting antinociceptive tolerance. Neurourosi 20, 7074–7079.

Yeoh, E. H., Reisli, R., Borazan, H., and Otelcioglu, S. (2012). A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: the protective effect of prior administration of ketamine. Anesth. Analg. 101, 1750–1756. doi: 10.1213/01.ANE.0000184136.20929.7f

Yarnuth, J., D’Angelo, R., Kerkhart, B., O’Leary, C., Pitts, M. C. H, Graef, G., et al. (1997). A comparison of remifentanil and morphine sulfate for acute postoperative
Kim et al. Opioid induced hyperalgesia of remifentanil

Yeom, J. H., Kim, K. H., Chon, M. S., Byun, J., and Cho, S. Y. (2012). Remifentanil used as adjuvant in general anesthesia for spinal fusion does not exhibit acute opioid tolerance. *Korean J. Anesthesiol.* 63, 103–107. doi: 10.4097/kjae.2012.63.2.103

Zarate, E., Sa Rego, M. M., White, P. F., Duffy, L., Shearer, V. E., Griffin, J. D., et al. (1999). Comparison of adenosine and remifentanil infusions as adjuvants to desflurane anesthesia. *Anesthesiology* 90, 956–963. doi: 10.1097/00000542-199904000-00005

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.